Full Press Release Details
EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery.
CRVO
EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery
Key Takeaway: EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery